Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ATIS is on the move! -- Ignore unavailable to you. Want to Upgrade?

To: Albert B. Kisselburgh who wrote (1198)	12/5/1997 6:40:00 PM
From: David S.	Read Replies (1) \| Respond to of 2205

ATIS has been on a road show for years. The best time to short this stock will be right after the product is approved.

To: Albert B. Kisselburgh who wrote (1198)	12/5/1997 10:53:00 PM
From: Marshall Teitelbaum	Read Replies (2) \| Respond to of 2205

Al, Sorry to babble away, but these were pretty serious issues that I wanted to clarify, at least as to my perception on the whole thing, once and for all. Hopefully this won't be a subject of confusion or redundancy any further....especially cause I get sick of typing pretty quickly. As to the "road show" aspect, you are right, but this can be interpreted in many ways, and mine is that it is marketing and pr. Trying to get the word out, especially after their credibility had been knocked over the last year or so, is an important part of their growth...no different for other companies. ATIS is still learning what is necessary in this area, as are all biotechs...uncharted territory. It would be nice to hear some of the details as to European progress by way of S&N though. Not sure I agree with David's thoughts here, although I know more than half of the time with biotechs there are selloffs on the news, at least initially. The difference here is that we're looking at a company which already has recently been well-shorted, and unless it goes up astronomically, it won't be hitting prices in uncharted territory...the psychological perception in my mind is that the price has been held back by all of the delays, and if it was worth upper teens to low 20s on good news in general, it sure has more legitimate reason to be there with news of substance. As we all know, business and investing are more about perception than anything else, especially in the biotech area. Guess we'll see just where the price goes this month, and what the short percentage is going into january. If it hasn't dropped substantially prior to the meeting, and it gets good news, it would be hard to believe that there wouldn't be some covering, etc. There was a slight drop in short % for november vs. october, but it was still a pretty significant number. Nevertheless, those who own below the current prices probably aren't in any danger at this point...imo. The main risk in my mind lies with what the fda has to say. For the moment though, it looks like 15 brings a bit of resistance, and gradual movement, as I've said before, would be healthiest for ATIS, and limit the likelihood of that sell on the news mentality. Now, about that watch you wanted.... :) Have a nice weekend , Marshall